Microarray-based identification of CUB-domain containing protein 1 as a potential prognostic marker in conventional renal cell carcinoma
- PMID: 18483744
- PMCID: PMC12161718
- DOI: 10.1007/s00432-008-0412-4
Microarray-based identification of CUB-domain containing protein 1 as a potential prognostic marker in conventional renal cell carcinoma
Abstract
Purpose: Renal cell carcinoma (RCC) is characterized by a variable and unpredictable clinical course. Thus, accurate prediction of the prognosis is important in clinical settings. We conducted microarray-based study to identify a novel prognostic marker in conventional RCC.
Patients and methods: The present study included the patients surgically treated at Kyoto University Hospital. Gene expression profiling of 39 samples was carried out to select candidate prognostic markers. Quantitative real-time PCR of 65 samples confirmed the microarray experiment results. Finally, we evaluated the significance of potential markers at their protein expression level by immunohistochemically analyzing 230 conventional RCC patients.
Results: Using expression profiling analysis, we identified 14 candidate genes whose expression levels predicted unfavorable disease-specific survival. Next, we examined the expression levels of nine candidate genes by quantitative real-time PCR and selected CUB-domain containing protein 1 (CDCP1) for further immunohistochemical analysis. Positive staining for CDCP1 inversely correlated with disease-specific and recurrence-free survivals. In multivariate analysis including clinical/pathological factors, CDCP1 staining was a significant predictor of disease-specific and recurrence-free survivals.
Conclusions: We identified CDCP1 as a potential prognostic marker for conventional RCC. Further studies might be required to confirm the prognostic value of CDCP1 and to understand its function in RCC progression.
Figures
Similar articles
-
mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.J Cancer Res Clin Oncol. 2019 Jan;145(1):153-163. doi: 10.1007/s00432-018-2775-5. Epub 2018 Oct 27. J Cancer Res Clin Oncol. 2019. PMID: 30368665 Free PMC article.
-
TET1 methylation and mRNA expression in renal cell carcinoma: implications for tumor staging and prognosis.Eur J Med Res. 2025 Aug 20;30(1):778. doi: 10.1186/s40001-025-03051-y. Eur J Med Res. 2025. PMID: 40830820 Free PMC article.
-
Cannabinoid receptor 2 as a novel target for promotion of renal cell carcinoma prognosis and progression.J Cancer Res Clin Oncol. 2018 Jan;144(1):39-52. doi: 10.1007/s00432-017-2527-y. Epub 2017 Oct 9. J Cancer Res Clin Oncol. 2018. PMID: 28993942 Free PMC article.
-
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340. Health Technol Assess. 2006. PMID: 16959170
-
Prognostic Significance of Hypoxia-Inducible Factor Expression in Renal Cell Carcinoma: A PRISMA-compliant Systematic Review and Meta-Analysis.Medicine (Baltimore). 2015 Sep;94(38):e1646. doi: 10.1097/MD.0000000000001646. Medicine (Baltimore). 2015. PMID: 26402839 Free PMC article.
Cited by
-
Identification of CD318, TSPAN8 and CD66c as target candidates for CAR T cell based immunotherapy of pancreatic adenocarcinoma.Nat Commun. 2021 Mar 5;12(1):1453. doi: 10.1038/s41467-021-21774-4. Nat Commun. 2021. PMID: 33674603 Free PMC article.
-
EGF inhibits constitutive internalization and palmitoylation-dependent degradation of membrane-spanning procancer CDCP1 promoting its availability on the cell surface.Oncogene. 2015 Mar 12;34(11):1375-83. doi: 10.1038/onc.2014.88. Epub 2014 Mar 31. Oncogene. 2015. PMID: 24681947
-
Inhibition of tumor metastasis: functional immune modulation of the CUB domain containing protein 1.Mol Pharm. 2010 Feb 1;7(1):245-53. doi: 10.1021/mp900236t. Mol Pharm. 2010. PMID: 19916495 Free PMC article.
-
Identification of CD318 (CDCP1) as novel prognostic marker in AML.Ann Hematol. 2020 Mar;99(3):477-486. doi: 10.1007/s00277-020-03907-9. Epub 2020 Jan 21. Ann Hematol. 2020. PMID: 31965270 Free PMC article.
-
Dysregulated expression of cell surface glycoprotein CDCP1 in prostate cancer.Oncotarget. 2015 Dec 22;6(41):43743-58. doi: 10.18632/oncotarget.6193. Oncotarget. 2015. PMID: 26497208 Free PMC article.
References
-
- Bodmer D, van den Hurk W, van Groningen JJ, Eleveld MJ, Martens GJ, Weterman MA, van Kessel AG (2002) Understanding familial and non-familial renal cell cancer. Hum Mol Genet 11:2489–2498 - PubMed
-
- Chuaqui RF, Bonner RF, Best CJ, Gillespie JW, Flaig MJ, Hewitt SM, Phillips JL, Krizman DB, Tangrea MA, Ahram M, Linehan WM, Knezevic V, Emmert-Buck MR (2002) Post-analysis follow-up and validation of microarray experiments. Nat Genet 32(Suppl):509–514 - PubMed
-
- Gleave ME, Elhilali M, Fradet Y, Davis I, Venner P, Saad F, Klotz LH, Moore MJ, Paton V, Bajamonde A (1998) Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med 338:1265–1271 - PubMed
-
- Goldstein NS (1999) Grading of renal cell carcinoma. Urol Clin North Am 26:637–642 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous